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VaccineSince 2012, H7N3 highly pathogenic avian influenza (HPAI) has produced negative economic and animal
welfare impacts on poultry in central Mexico. In the present study, chickens were vaccinated with two
different recombinant fowlpox virus vaccines (rFPV-H7/3002 with 2015 H7 hemagglutinin [HA] gene
insert, and rFPV-H7/2155 with 2002 H7 HA gene insert), and were then challenged three weeks later with
H7N3 HPAI virus (A/chicken/Jalisco/CPA-37905/2015). The rFPV-H7/3002 vaccine conferred 100% protec-
tion against mortality and morbidity, and significantly reduced virus shed titers from the respiratory and
gastrointestinal tracts. In contrast, 100% of sham and rFPV-H7/2155 vaccinated birds shed virus at higher
titers and died within 4 days. Pre- (15/20) and post- (20/20) challenge serum of birds vaccinated with
rFPV-H7/3002 had antibodies detectable by hemagglutination inhibition (HI) assay using challenge virus
antigen. However, only a few birds (3/20) in the rFPV-H7/2155 vaccinated group had antibodies that
reacted against the challenge strain but all birds had antibodies that reacted against the homologous vac-
cine antigen (A/turkey/Virginia/SEP-66/2002) (20/20). One possible explanation for differences in vacci-
nes efficacy is the antigenic drift between circulating viruses and vaccines. Molecular analysis
demonstrated that the Mexican H7N3 strains have continued to rapidly evolve since 2012. In addition,
we identified in silico three potential new N-glycosylation sites on the globular head of the H7 HA of
A/chicken/Jalisco/CPA-37905/2015 challenge virus, which were absent in 2012 H7N3 outbreak virus.
Our results suggested that mutations in the HA antigenic sites including increased glycosylation sites,
accumulated in the new circulating Mexican H7 HPAIV strains, altered the recognition of neutralizing
antibodies from the older vaccine strain rFPV-H7/2155. Therefore, the protective efficacy of novel
rFPV-H7/3002 against recent outbreak Mexican H7N3 HPAIV confirms the importance of frequent updat-
ing of vaccines seed strains for long-term effective control of H7 HPAI virus.
Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.
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M.F. Criado et al. / Vaccine 37 (2019) 2232–2243 22331. Introduction protect chickens against challenge with H7N3 HPAIV isolated fromThe H5 and H7 highly pathogenic (HP) avian influenza (AI)
viruses (HPAIV) have been one of the most frequent causes of sev-
ere poultry outbreaks around the world [1,2]. Recently, the H7N3
HPAI in Mexico has caused dramatic negative economic and social
impacts due to a high number of poultry losses from deaths and
culling. First reported in June 2012, the H7N3 HPAI has affected
over 22 million chickens in Jalisco State, Mexico’s most important
table egg producing area [2,3]. Simultaneously, an immunization
campaign using H7 inactivated virus [A/cinnamon teal/Mex-
ico/2817/2006 (H7N3) vaccine strain], and several measures were
established to control the disease including quarantine of affected
premises, depopulation of infected poultry, and enhanced surveil-
lance for infection in birds [3]. The initial vaccine seed strain
(A/cinnamon teal/Mexico/2817/2006 [H7N3] vaccine strain) was
protective against the June 2012 outbreak virus (A/chicken/Jalisco/
CPA-12283/2012 [H7N3], Jalisco/12283/2012) [4–6]. Since 2013,
additional H7N3 HPAIV outbreaks have occurred and affected
primarily layers, but also some broilers, breeders, and backyard
poultry in the Mexico States of Jalisco, Aguascalientes, Guanajuato
and Puebla [2]. Recently, two outbreaks of H7N3 HPAI in Mexico
were reported by OIE (World Organization for Animal Health)
demonstrating the outbreaks are continuing [7]. Previous studies
have characterized the pathobiology of H7N3 HPAIV, and effective-
ness of different vaccine seeds strains on protection [4–6]. The vac-
cine trials have shown variable efficacy, with older H7 vaccine seed
strains providing poor protection due to a combination of genetic
and antigenic distance and low immunogenicity [4–6]. Outbreaks
of H7N3 HPAI in vaccinated flocks have been reported in Mexico
since 2016 [8].
A recombinant fowlpox vaccine (rFPV) expressing HA from H5
LPAIV (A/turkey/Ireland/1378/1983) has been licensed and suc-
cessfully used during the last twenty years in Mexico and other
countries in Central America for immunization at 1-day-of-age
[1], but there is no similarly licensed rFPV-H7 AIV available in
Mexico for hatchery vaccination and induction of early immunity.
An experimental vaccine, rFPV-H7/2155 was previously tested by
our group and found to be protective when used alone or can
enhance the licensed inactivated H7N3 AIV vaccine in a prime-
boost vaccination regime [5].
Efficacious AIV vaccines have demonstrated protection against
morbidity and mortality from HPAIV challenge and have reduced
viral shedding from the respiratory and gastrointestinal tract of
birds [1,9]. In developing countries, poultry vaccination has been
an important control tool in combination with depopulation of
infected poultry, biosecurity measures, education, rapid diagnostic,
and surveillance to control HPAIV [1,9]. However, mutations of
influenza A virus, especially in the HA gene, have resulted in loss
of vaccine optimal efficacy, hindering HPAIV control [9–11]. Muta-
tions in the AIV genomes have generated changes responsible for
antigenic drift and loss of protection by some vaccine seed strains
[2,12]. Furthermore, within influenza A viruses, the acquisition of
N-glycosylation has prevented neutralization by antibodies
directed against previous strains and escaped vaccine-induced
immunity elicited by heterologous vaccines [13–16]. Therefore,
the N-glycosylation of HA also can influence antigenicity and thus
play an important role in candidate influenza A vaccine strain
selection and vaccination effectiveness against newly emerging
field viruses [15,17,18].
Our goal was to analyze the protective efficacy of two different
constructs of recombinant fowlpox virus vaccine (rFPV) containing
a 2002 (rFPV-H7/2155) and 2015 (rFPV-H7/3002) H7 low
pathogenicity avian influenza (LPAI) virus (LPAIV) HA inserts toa recent outbreak in Mexico, A/chicken/Jalisco/CPA-37905/2015
(Jalisco/37905/2015). Protective efficacy was determined by ana-
lyzing morbidity and mortality rates, titer of challenge virus shed,
and pre-challenge serum antibody levels. Phylogenetic analysis
was accomplished to understand the antigenic variation in the
H7 HA from Mexico in comparison to historical North American
lineage H7 AIV. Molecular analysis of H7 HA, as amino acid substi-
tutions, protein structure, and N-glycosylation were evaluated to
understand the possibilities of how the HA antigenicity could have
contributed to field virus escape from vaccine-induced immunity.2. Materials and methods
2.1. Animals
One-day-old SPF White leghorn chickens were housed sepa-
rately by group in negative pressure isolators with HEPA-filtered
intake air in an ABSL-2 facility (Merial/Boehringer-Ingelheim) for
first 3 weeks of the study, and subsequently transferred to ABSL-
3 enhanced facility (Southeast Poultry Research Laboratory) for
HPAIV challenge. Birds had ad libitum access to feed and water
throughout the experiment. All procedures were performed in
accordance with the protocol approved by the Institutional Labora-
tory Animal Care and Use Committee.
2.2. Viruses and vaccines
The H7N3 HPAIV, A/chicken/Jalisco/CPA-37905/2015
(Jalisco/37905/2015), (GenBank accession number MH342039)
was isolated from a backyard chicken during 2015 in the state of
Jalisco, Mexico (courtesy of MVZ Joaquín B. D. Álvarez and Mario
Solís Hernández, Servicio Nacional de Sanidad, Inocuidad y Calidad
Agroalimentaria [SENASICA], Mexico). The virus was propagated
and titrated by allantoic sac inoculation of 9–10 day-old embry-
onating chicken eggs (ECE) by standard methods [19] and used
as a challenge virus in this study.
Two constructs of recombinant fowlpox virus vector each con-
taining a single H7 LPAIV gene insert (rFPV-H7-AIV) from: (1)
North American strain A/turkey/Virginia/SEP-66/2002 (H7N2,
GenBank accession number AY240913) (rFPV-H7/2155) or (2) the
Mexican strain A/chicken/Guanajuato/07437-15/2015 (H7N3,
GenBank accession number AKL91078.1) (rFPV-H7/3002) were
constructed the same way as the licensed TROVAC-H5 and tested
in this experiment. The fowlpox vector for TROVAC-H5 was
derived from the vaccine strain contained in the DIFTOSEC fowlpox
vaccine. TROVAC-H5 received license in the United States in 1998
and has since been used in Mexico, Guatemala, El Salvador, and
Vietnam [20].
2.3. Experimental design and sampling
Experiment design and sampling were done using animals, vac-
cination, and challenge protocols following identical conditions as
previously published from our group [5]. In summary, sixty chick-
ens were distributed into three groups of twenty birds each and
were given an individual identification number. All birds were vac-
cinated at one-day of age by the subcutaneous (SQ) route, at a dose
of 103.5 50 percent embryo infectious doses (EID50) in 0.2 ml per
bird. Groups 1 and 2 were inoculated with the rFPV-H7-AIV vacci-
nes: rFPV-H7/3002 and rFPV-H7/2155, respectively. Group 3
(Sham) received the rFPV-H7-AIV vaccine diluent. Three-weeks
post-vaccination (21-days-of-age), birds were bled to evaluate
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with 106 EID50 of HPAIV H7N3, Jalisco/37905/2015, in a volume
of 0.1 ml. The inoculum titer was verified as 105.9 EID50/0.1 ml by
back titration in ECE.
Oropharyngeal (OP), which includes swabbing the choanal cleft,
and cloacal (CL) swabs were collected at 2- and 4-days post-
challenge (dpc), placed in Becton-Dickinson BBL brain heart infu-
sion (BHI) medium with 2X antibiotics (Penicillin/Streptomycin/F
ungiezone; Hyclone, Logan, UT, USA), and stored at 80 C until
tested to determine virus shed titers. All chickens were observed
daily for clinical signs and mortality from 0 to 14 dpc. Chickens,
which were euthanized for humane reasons when clinical symp-
toms as severe listlessness, neurological signs, respiratory distress,
or others HPAI infection signs, were counted as dead the next day
for mean death time calculations. At the end of the experiment
(14 dpc, 5-weeks-of-age), surviving birds were bled to evaluate
antibody titers and euthanized according to the approved IACUC
protocol.
2.4. Determination of virus shedding
OP and CL swabs were processed for quantitative real-time RT-
PCR (qRRT-PCR) to determine the HPAIV viral load from the
oropharynx and gastrointestinal tract on 2 and 4 dpc. This method-
ology has been used as standard protocol among published veteri-
nary influenza vaccine studies. As published [21], the protocol
demonstrated the high correlation between qRRT-PCR quantity
and infectious titers when: (a) using only influenza A challenge
viruses chicken adapted and propagated in embryonating chicken
eggs (ECE), (b) using low MOI to inoculate ECE in propagating
the viruses to generate the challenge inoculum which minimizes
defective interfering (DI) RNAs, and (c) using the same specific
challenge virus stock to generate the standard curve with each
dilution point directly comparing qRRT-PCR CT values and infec-
tious titer.
Briefly, in this study the viral RNA from OP and CL swabs was
extracted using MagMAXTM-96 AI/ND Viral RNA Isolation Kit
(ThermoFisher Scientific, Carlsbad, CA, USA) following the manu-
facturer’s instruction. Further, qRRT-PCR assay was performed as
previously described [22] using the AgPath-ID One-step RT-PCR
kit (ThermoFisher Scientific) with primers and probe targeting
the influenza matrix gene. Samples were run on the 7500 FAST Real
time PCR System (Applied Biosystems, Foster City, CA, USA). For
viral quantification, a standard curve was established with viral
RNA extracted from 10-fold dilutions of the challenge virus [23],
Jalisco/37905/2015. Results were reported as log10 EID50/ml and
the lower limit of detection was 1.1 log10 EID50/ml; therefore
qRRT-PCR negative samples were treated as 1.0 log10 EID50/ml for
statistical purposes.
2.5. Serology
The serum collected pre- and post-challenge was used in
hemagglutination inhibition (HI) assay to determine the antibody
levels in the vaccinated birds. The antigens were prepared as pre-
viously described [24] and the HI assays were performed according
to standard protocol [25]. The challenge virus, Jalisco/37905/2015
was used as antigen in the HI with each of the 3 groups of vacci-
nated birds (rFPV-H7/3002, rFPV-H7/2155, and Sham). To confirm
vaccination, the rFPV-H7/2155 vaccinated group was also tested
with the homologous vaccine antigen, A/turkey/Virginia/SEP-
66/2002 (H7N2). To observe differences in serological response
we tested the sera from rFPV-H7/2155-vaccinated birds with the
challenge virus, Jalisco/37905/2015, and virus from the first
H7N3 outbreak in Mexico, Jalisco/12283/2012, as antigens. Titers
were expressed as geometric mean titers (GMT-log2). Samples withtiters below 3 log2 GMT were considered negative, and then
assigned as 2 log2 GMT for statistical purpose.
2.6. Phylogenetic analysis for complete HA gene of H7 avian influenza
viruses
A phylogenetic tree was created by the Maximum-likelihood
(ML) algorithm for the HA gene of H7 avian influenza viruses. All
available complete HA gene sequences identified from North
America, South America, Asia, and Europe (n = 2135) were
retrieved from the Influenza Virus Resource database (http://
www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) on October 18,
2017. The sequences were pruned by using the software cd-hit
[26] at 97% homology to filter-out 92 representative sequences.
The nucleotide sequences of HA segment from 2015 to 2016
sequenced in this study (n = 5) and all Mexican H7 viruses avail-
able in the GenBank (n = 17) were added to the dataset. A total
of 114 nucleotide sequences were aligned using MAFFT and man-
ual editing of alignments were performed in Geneious 8 software
[27]. The ML tree was estimated by the RAxML software [28] using
the general time-reversible model of nucleotide substitution. Boot-
strap support values were generated by using 500 rapid bootstrap
replicates. The ML phylogenetic tree was visualized with MEGA 7
software (http://www.megasoftware.net). Bootstrap values >70%
are shown at the branch nodes.
2.7. Molecular characterization of H7 hemagglutinin: residues, N-
glycosylation sites, and protein structure
The molecular characterization of H7 hemagglutinin of the chal-
lenge virus (Jalisco/37905/2015), vaccines (rFPV-H7/2155 and
rFPV-H7/3002) were performed using different methodologies.
The virus from 2012 outbreak in Mexico, Jalisco/12283/2012, was
included in the molecular analyses for comparison with the chal-
lenge virus, Jalisco/37905/2015, isolated in a recent outbreak.
The HA sequence were used for alignment and residue analysis
in the Lasergene 12 using Clustal W, MegAlign software (DNA
STAR, Madison, WI). The potential N-glycosylation sites were pre-
dicted using NetNGlyc server 1.0 [29,30]. The HA structure was
modelling using the H7 HA template (PDB accession number,
3M5G) in the SWISS-MODEL server [31–33]. The 3D molecular
HA structures were visualized using the PyMOL Molecular Graph-
ics System (Version 2.0 Schrödinger, LLC).
2.8. Deglycosylation of hemagglutinin
A reaction for removal of glycans from the HA protein (deglyco-
sylation) was conducted to identify the N-glycosylation sites in the
HA. Samples were digested with peptide N-Glycosidase F (PNGase
F) kit (New England Biolabs, Ipswich, MA, USA) according to the
manufactured instructions. Briefly, the glycoproteins were dena-
tured with 1X of Glycoprotein Denaturing Buffer at 100 C for
10 min. Further, the mixture of 1X of GlycoBuffer, 1% NP40, water
and PNGase F were added to the reaction followed by incubation of
37 C for 1 h. The reaction was heat inactivated at 75 C for 15 min.
Samples were loaded in the SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE) and the molecular weight of AI HA analyzed by
western blot using antisera against H7N3 [A/turkey/OR/1971
(H7N3)].
2.9. Western blot assay
Sample homogenates were prepared in Laemmli buffer v/v
(62.5 mM Tris–HCl pH 6.8; 5% b-mercaptoethanol; 2%SDS; 20%
glycerol; 0.01% bromophenol blue) (Bio-Rad, Hercules, CA, USA)
and denatured 5 min at 95 C. Samples were then separate on
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1X Tris/Glycine/SDS buffer (Bio-Rad) and transferred to nitrocellu-
lose membrane using liquid electrophoresis systems CriterionTM
Vertical Electrophoresis Cell (Bio-Rad). The nitrocellulose mem-
brane was blocked with 5% nonfat dry milk in Tris-buffered saline
with Tween 20 (TBST) buffer (20 mM Tris, pH 7.5, 150 mM NaCl,
0.1% Tween 20) during 1 h at room temperature, and then
incubated overnight at 4 C with chicken antisera against H7N3
(A/turkey/OR/1971) at a dilution of 1:2000. The membrane was
washed with TBST and incubated with an alkaline phosphatase
(AP) labelled goat anti-chicken IgY (H + L) (Thermo Fisher Scien-
tific, Rockford, IL, USA) diluted 1:10,000. The western blot was
visualized with the substrate BCIP/NBT (Sigma-Aldrich) according
the manufacturers protocol. The molecular size of the HA pre-
and post-digestion with PNGase F was analyzed with the marker
Precision Plus Protein Dual Xtra Standard (Biorad).2.10. Statistical analysis
Statistical analyses were performed using Prism 7 (GraphPad
software, San Diego, CA, USA). The survival rate data was analyzed
using the Mantel-Cox Log-Rank test. Fisher’s exact test was used to
analyze statistical significance of virus shedding. Statistical differ-
ences in mean viral titers and antibody levels between groups were
analyzed using Mann–Whitney test and Tukey one-way ANOVA. A
P-value of <0.05 was considered to be significant.3. Results
3.1. Morbidity and mortality in specific pathogen free (SPF) White
Leghorn chickens challenged with HPAIV H7N3
One-day-old chickens were vaccinated once and challenged
three weeks later with H7N3 HPAIV, Jalisco/37905/2015 (H7N3).
After challenge, all the sham-vaccinated control birds developed
acute severe clinical disease and died between 2 and 4 days post-
challenge (dpc) (mean death time [MDT] = 3.20 days) (Table 1,
Fig. 1). Most of the sham-vaccinated birds were found dead
(11/20) but others (9/20) showed clinical signs like respiratory dis-
tress, listlessness, lethargy, and prostration. The latter were eutha-Table 1
Summary data from one-day-old WL chickens vaccinated with one of two constructs of rec
challenged with Jalisco/37905/2015 H7N3 HPAIV.
Group Vaccinea N of birds Morbidityb Mortalityb MDTc Oral sheddingd
2 dpc 4
1 rFPV-H7/3002 20 0/20 0/20 na 07/20 (1.5) 05
2 rFPV-H7/2155 20 20/20 20/20 3.2 20/20 (4.8) 3/
3 Sham 20 20/20 20/20 3.2 20/20 (4.9) 1/
a Constructs of recombinant fowlpox virus vaccine containing an H7 LPAIV gene insert.
Guanajuato/07437-15/2015 (H7N3), and group 2, rFPV-H7/2155 vaccine, the HA from No
the cleavage site changed back to LPAIV.
b Morbidity = no. with clinical disease/total; mortality = no. survivors/total.
c MDT, mean death time, *#dead birds  dpc/total dead birds (expressed as dpc, days
d The numbers represent no. virus positive/total in group followed by mean virus shed
was 1.1 log10 EID50/ml; therefore qRRT-PCR negative samples were treated as 1.1 log10
assigned the value of 1.0 log10 EID50/ml. Different superscript lowercase denotes statistica
by Fisher Exact (p < 0.05). Different superscript uppercase denotes statistical significance
and ANOVA (p < 0.05). §, number of positive birds was too low for statistical purposes.
e The numbers represent no. serology positive/total in group (geometric mean titers (
virus or challenge virus. Samples with titers below 3 log2 GMT were considered negativ
* = The challenge virus and vaccine rFPV-H7/3002 are nearly identical, then only challennatized for humane reasons. Similar clinical results were observed
for all rFPV-H7/2155 vaccinated birds (MDT = 3.15 days) (Table 1,
Fig. 1); i.e. birds were not protected against challenge, and conse-
quently had severe clinical signs (7/20) or died (13/20) within
4 dpc. By contrast, all rFPV-H7/3002 vaccinated birds had complete
protection from clinical signs and death (Table 1, Fig. 1).
3.2. Evaluation of virus shedding
Virus shedding was evaluated by quantification of AIV RNA in
OP and CL swabs from chickens at 2 and 4 dpc using qRRT-PCR
[21]. Viral RNA was detected at 2 dpc in OP and CL swabs from
all birds in the sham group, with mean titer of 4.9 and 6.4 log10
EID50/ml, respectively. Similar results were observed for birds in
the rFPV-H7/2155 group, with 4.8 log10 EID50/ml (OP) and 5.9
log10 EID50/ml (CL) titers (Table 1, Fig. 2). At 4 dpc, only one bird
survived in the sham group with a viral titer in the OP and CL sam-
ples, 5.8 and 7.7 log10 EID50/ml, respectively. In the rFPV-H7/2155
vaccine group, only three birds were alive at 4 dpc and shed virus
both orally, mean titer of 4.4 log10 EID50/ml, and cloacally, 6.2 log10
EID50/ml (Table 1, Fig. 2).
In contrast, rFPV-H7/3002 vaccinated birds had either no or
very low viral shedding titers. The mean virus titer shed in the
CL samples was 2.7 (15/20) and 1.9 (12/20) log10 EID50/ml at 2
and 4 dpc, respectively. Interestingly, in the rFPV-H7/3002-
vaccinated group only 7/20 birds were positive at 2dpc and 5/20
were positive at 4 dpc for OP with a mean titer of 1.5 log10
EID50/ml on both days (Table 1, Fig. 2).
Overall, rFPV-H7/3002 vaccinated birds had statistically signifi-
cant lower OP and CL titers than sham and rFPV-H7/2155 vacci-
nated groups, and significantly fewer birds shedding virus from
the respiratory tract (p < 0.05) (Fig. 2).
3.3. Antibody levels in immunized birds pre- and post-challenge with
HPAIV H7N3
Sera collected from all chickens pre- (0 dpc) and the survivors at
termination (14 dpc) were processed for HI assay to measure
humoral immune response to the challenge virus antigen and vac-
cine seed strain (Table 1, Fig. 3). Sera from sham-vaccinated chick-
ens were negative for anti-AIV antibodies on the day of challenge.ombinant fowlpox virus vaccine, rFPV-H7/3002 and rFPV-H7/2155, and subsequently
Cloacal sheddingd HI serologye
Vaccine
strain as
antigen
Jalisco/37905/2015 as
antigen
dpc 2 dpc 4 dpc Pre-
challenge
Pre-
challenge
Post-
challenge
/20 (1.5) 15/20 (2.7) 12/20 (1.9) nd * 15/20 (3.0) 20/20 (5.0)
3 (4.4) 20/20 (5.9) 3/3 (6.2) 20/20 (6.6) 3/20 (2.2) nd
1 (5.8) 20/20 (6.4) 1/1 (7.7) nd 00/20 (2.0) nd
Group 1, rFPV-H7/3002 vaccine, contain the HA from the Mexican strain A/chicken/
rth American strain A/turkey/VA/SEP-66/2002 (H7N2). Important, the HA gene had
post-challenge).
titer. Results were reported as log10 EID50 titer/ml and the lower limit of detection
EID50/ml. For the purposes of statistical calculations, all the negative samples were
l significance of number of birds shedding between vaccine and corresponding sham
of shedding titers between vaccine and corresponding sham by Mann-Whitney test
GMT-log2) only includes positive birds) followed by mean HI titers against vaccine
e, and then assigned as 2 log2 GMT for statistical purpose. nd = not determined. nd
ge virus was used as HI antigen in this vaccinated group.
Fig. 1. Survival curve of vaccinated chickens challenged with Jalisco/37905/2015 (H7N3) HPAIV.
Fig. 2. Scatter plot of oropharyngeal (OP) and cloacal (CL) shedding detected by qRRT-PCR after challenge with the Jalisco/37905/2015 (H7N3) HPAIV. Viral titers in swabs
from vaccinated birds, rFPV-H7/3002, rFPV-H7/2155, and Sham, at 2 and 4 days post challenge (dpc) are expressed as log10 EID50/ml. The limit of detection was 1.1 log10
EID50/ml and negative samples were treated as 1.0 log10 EID50/ml. Statistical significance between mean titers was determined with ANOVA using the Tukey’s Multiple
Comparison Test (p < 0.05). The p < 0.005 are indicated by ‘‘**”.
2236 M.F. Criado et al. / Vaccine 37 (2019) 2232–2243The pre-challenge serum from rFPV-H7/2155 vaccinated group had
low levels of antibody (log2 GMT = 2.2) in a few birds (3/20) when
using the challenge virus as the antigen (Table 1, Fig. 3a). However,
when using the vaccine seed as antigen (A/turkey/VA/SEP-
66/2002), all birds (20/20) had high titers of HI antibody (log2
GMT = 6.6) (Table 1, Fig. 3b), and when using Jalisco/12283/2012
(13/20), a high number of birds (13/20) had specific antibodies
(Fig. 3c), confirming results previously published [5]. Therefore,
the r-FPV-H7/2155 vaccinated-birds have specific antibodies that
significantly (p < 0.05) recognize the virus from the first outbreak
in 2012, as Jalisco/12283/2012, than Jalisco/37905/2015 (Fig. 3c).
In contrast, the rFPV-H7/3002 vaccinated birds had HI antibod-
ies in the pre- (15/20, log2 GMT = 3) and post- (20/20, log2
GMT = 5) challenge serum when using the challenge virus
(Jalisco/37905/2015) as HI antigen (Fig. 3a), and when using
Jalisco/12283/2012 (6/20), a few number of birds (6/20) had speci-
fic antibodies (Fig. 3c).3.4. Molecular analysis of H7 avian influenza virus
To understand the role of HA in the protection of chickens
against challenge with H7N3 HPAIV, we compared the nucleotide
identity for complete HA, specific amino acid sequences, and pro-
tein structure between HA of vaccine viruses and challenge strain.
The ML phylogenetic tree indicates the initial Mexican H7N3
HPAIV strain from June 2012 emerged from a North American H7
LPAIV lineage. Since then, it evolved through genetic drift to create
the three contemporary genetic subgroups (I, II, and III) during
2015 and 2016 (Fig. 4a). We observed that the HA gene of the chal-
lenge virus (Jalisco/37905/2015) and the H7 strain in the rFPV-
H7/2155 (A/turkey/Virginia/SEP-66/2002) had lower nucleotide
identity (86.5%). The Jalisco/37905/2015 and the HA of rFPV-
H7/3002 vaccine [H7 from 2015 strain (A/chicken/Mexico/2015)]
not only had a higher identity (99.2%) but also cluster together in
subgroup II.
(a)
(b)
(c)
Fig. 3. Scatter plot of HI titers for vaccinated birds in groups, rFPV-H7/3002, rFPV-H7/2155, and Sham pre- and post-challenge. The HI titers were analyzed using the
challenge virus (A), or vaccine strain as antigen (B), or Jalisco/12283/2012 as antigen (C). Titers were expressed as geometric mean titers (GMT-log2), and samples with titers
below 3 log2 GMT were considered negative. Dotted horizontal lines indicate limit of detection. Statistical significance between mean titers was determined with ANOVA
using the Tukey’s multiple comparison and Mann–Whitney tests or t-test (p < 0.05). The p < 0.05 and p < 0.005 are indicated by ‘‘* ‘‘and ‘‘**”, respectively. ns = birds did not
survive.
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tions in the HA of the challenge virus (Jalisco/37905/2015), vacci-
nes (rFPV-H7/2155 and rFPV-H7/3002), and the initial MexicanH7N3 HPAIV outbreak strain (Jalisco/12283/2012). The
Jalisco/12283/2012 strain was chosen for comparison because a
previous study, the rFPV-H7/2155 vaccine provided 100%
2238 M.F. Criado et al. / Vaccine 37 (2019) 2232–2243protection from mortality against this lethal challenge strain [5].
The percentage of amino acid similarities among the HA sequences
ranged from 98.6 to 87.3%. The HA gene in the early strains (vac-
cine rFPV-H7/2155 and Jalisco/12283/2012) showed few amino
acid differences. However, when we compared these strains to
HA of the new vaccine (rFPV-H7/3002) and the Jalisco/37905/2015,
there was progressive accumulation of mutations from the early to
recent strains (Fig. 4b). The majority of the amino acid substitu-
tions are localized in the globular head of HA. Furthermore, these
changes occurred in regions close or inside the antigenic sitesFig. 4. Molecular analysis of H7 avian influenza virus hemagglutinin. (A) Phylogenetic
influenza viruses. Available full-length HA gene sequence identified from North Ameri
database were used. The vaccine strains and challenge virus used in this study are high
shown at the branch nodes. (B) Amino acids residues of AIV H7 HA were aligned in Laserg
boxes. Only the amino acids different from those in the challenge virus (Jalisco/37905
glycosylation sites are shown in blue (position 30, 46, 249, and 501) and red (position
samples analyzed, and red are exclusive to the Jalisco/37905/2015 and vaccine rFPV-H7/3
antigenic sites A (cyan), B (orange), C (magenta), D (green), and E (yellow) are labeled. Loc
(position 141, 151, and 182) and blue color (position 30, 46, 249, and 501). Antigenic si
Jalisco/37905/2015HA treated with (+) and without () PNGase F. The HA was detected u
N-glycans with and without PNGase treatment was shown as ‘‘HA N-Glyc”. Results are r
color in this figure legend, the reader is referred to the web version of this article.)(Fig. 4b). Some of these amino acid substitutions resulted in the
formation of potential new predicted glycosylation sites.
Thus, we examined in silica the differences in the number of
potential of N-glycosylation sites in the HA sequence (Fig. 4c). Posi-
tions 30, 46, 249, and 501 had potential glycosylation sites in
Jalisco/12283/2012 virus, in which position 249 was the only one
localized in the globular head. However, between late 2012 and
early 2016, H7N3 Mexican strains obtained additional glycosyla-
tion sites in the globular head of the HA protein at the
positions 141, 151 and 182: 1) subgroup I  141 and 151, 2)tree created by the Maximum-likelihood algorithm for the HA gene of H7 avian
ca, South America, Asia, and Europe (n = 2135) from the Influenza Virus Resource
lighted as black circles () and triangle (N), respectively. Bootstrap values >80% are
ene MegAlign (DNAStar). Antigenic sites of H3 HA (A, B, C, D, and E) are shown in the
/2015) sequence are shown. The asterisks represent the position of predicted N-
141, 151, and 182). The N-glycosylation sites shown in blue were observed in all
002. (C) Ribbon diagram and surface of H7 HA. Only monomers are shown. Predicted
ations of predicted N-glycosylation sites are represented as spheres labeled with red
tes A and E are highlighted. D) Western blot comparison of Jalisco/12283/2012 and
sing chicken antiserum against H7N3 (A/turkey/OR/1971). The number of predicted
epresentative of two independent replicates. (For interpretation of the references to
(b)
Fig. 4 (continued)
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Specifically, the challenge virus (Jalisco/37905/2015) (Fig. 4b and
c), which belongs to subgroup II, has additional potential N-
glycosylation sites at the positions: 141, 151 and 182. Moreover,
two of these sites, positions 151 and 182, were found within anti-
genic sites A and E, respectively. Protein alignment and prediction
of N-glycosylation sites determine the structure of H7 HA from
these strains affected the protein structure and possibly immune
recognition in the antigenic sites (Fig. 4c).
To verify the in silico prediction of potential N-glycosylation
sites in the Mexican H7 HA, we used pre-and post-digestion with
PNGase F followed by SDS-PAGE. Western blot analysis demon-
strated the HA of Jalisco/37905/2015 had a higher molecular
weight than HA of Jalisco/12283/2012 (Fig. 4d). Moreover, PNGAse
F treatment, which removes the N-link glycans, resulted in a
decrease of the molecular weight of all HA to a similar size
(Fig. 4d). Therefore, these results demonstrated that potentialN-glycosylation sites were present in different quantities in the
HA proteins of the Mexican viruses from 2012 (Jalisco/12283/2012)
and 2015 (Jalisco/37905/2015) outbreaks, as predicted in silico.4. Discussion
Both H5 and H7 HPAIV are the most frequent causes of severe
disease outbreaks in poultry [2,34]. In developing countries, the
use of vaccines is an important tool to control HPAI in combination
with depopulation of infected poultry, strict epidemiological
surveillance, and enhanced biosecurity measures [35]. However,
continuous genetic evolution of H5 and H7 AIVs, as accumulation
of nucleotides and amino acids substitutions in the HA, has led
to significant antigenic diversity of these AIVs in poultry in many
parts of the world [36–39]. Such diversity has led to antigenic drift
allowing AIVs to evade the herd immunity established from
(c)
(d)
Fig. 4 (continued)
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vaccines must be periodically re-evaluated to determine the effec-
tiveness against emergent variant circulating virus strains andshould be replaced with updated vaccine seed strains if no longer
protective. Outbreaks of H7N3 HPAI have been reported in vacci-
nated flocks in Mexico since 2016, suggesting significant antigenic
M.F. Criado et al. / Vaccine 37 (2019) 2232–2243 2241changes in the field viruses and a need to examine vaccine seed
strains for needed updates [8].
In the current study, immunization of one-day-old SPF White
Leghorn chickens with two different constructs of recombinant
fowlpox virus vaccine (rFPV-H7/3002 and rFPV-H7/2155), contain-
ing a 2002 and 2015 LPAI H7 HA insert, respectively, were used to
evaluate the protection against an H7N3 HPAI virus isolated in
Mexico during 2015 (Jalisco/37905/2015). Interestingly, the closely
related rFPV-H7/3002 vaccine conferred protection without mor-
bidity or mortality together with no or low virus shedding from
the respiratory and gastrointestinal tracts. A different scenario
was observed for birds vaccinated with the old vaccine, rFPV-
H7/2155, which previously conferred complete protection result-
ing in no clinical signs or death against the 2012 original outbreak
virus (Jalisco/122083/2012) [5]. Our results showed that rFPV-
H7/2155 and sham vaccinated birds after challenge with
Jalisco/37905/2015 had 100% mortality within 4 dpc.
Previous studies have demonstrated that systemic humoral
immunity induced by AI vaccines, especially HA subtype specific,
contributed to protection against influenza [1,9]. Most of the
rFPV-H7/3002-vaccinated birds had pre- and post-challenge HI
antibodies titers against the challenge virus, which conferred pro-
tection. Even though the rFPV-H7/2155 vaccine induced a strong
immune response against the homologous vaccine antigen, these
HI antibodies were not sufficiently specific to confer any protection
against the challenge virus. Antigenic differences between the old
vaccine strain (rFPV-H7/2155) and the current challenge strain
resulted in the recent H7N3 HPAI virus being poorly recognized
by antibodies from the rFPV-H7/2155 vaccine. This difference
was probably caused by antigenic drift in field isolates of H7N3
virus. In addition to a correlation between HA antibodies response
and protection against influenza, the cellular immune response
also can contribute to protection after vaccination [1,35]. In our
study, the influence of cell-mediated immunity (CMI) perhaps con-
tributed to the post-challenge protection of a few rFPV-H7/3002-
vaccinated birds (5/20) which lacked pre-challenge HI antibodies,
but were protected from morbidity and mortality. Future studies
are needed to better understand the mechanisms and benefits that
CMI could offer to vaccine effectiveness in poultry.
To better understand the difference observed in vaccine protec-
tion, nucleotide and amino acid sequences of the HA were further
analyzed to identify possible antigenic changes in the evolving H7
HPAIV viruses in Mexico. The HA phylogenetic tree suggested that
Jalisco/12283/2012 emerged from a North American H7 LPAIV lin-
eage and evolved to create multiple subgroups as early as 2015,
which includes the challenge virus used in this study,
Jalisco/37905/2015. The amino acid sequence analysis showed that
the challenge virus, Jalisco/37985/2015, and the original outbreak
virus, Jalisco/12283/2012, have 94.72% of HA identity. Similarity
of the whole HA sequence is not predictive of protection because
a few specific changes in amino acid sequence or tertiary structure
of HA protein can result in a lack of protection. In this case, the dif-
ference in the HA identity was the result of amino acid substitu-
tions, especially in the globular head of HA, in regions close or
inside the antigenic sites. It is well known that changes at the anti-
genic sites affect the specificity of neutralizing antibodies, but the
trigger for when antigenic changes requires a vaccine change is not
defined [1]. Overall, the amino acid substitutions at position 143
(alanine to threonine), 151 (glycine to asparagine), 152 (serine to
proline), and 184 (proline to serine) from early to recent H7 AIV
(Fig. 4b) suggest the formation of additional potential glycosylation
sites according to in silico analyses.
Interestingly, we observed that H7 Mexican AIV strains have
obtained potential additional glycosylation sites between June
2012, early 2015, and 2016. In silico analysis showed that 2 to 3
additional N-glycosylation sites were present on the globular headof the H7 HA. Recent advances in the interaction between AIV gly-
can and components of innate and adaptive immunity have been
providing insights regarding the ability of N-glycans to target
specific cells and consequently stimulate cytokines production
[13,16,41]. The effect of glycosylation on the HA tertiary structure
and possible immune recognition has been documented
[13–15,42–44]. The progressive accumulation of N-glycan on the
HA can physically mask access to antigenic sites allowing escape
from antibody-mediated response produced against previous field
strains and vaccine-induced immunity [13–15,44]. At the same
time, additional glycosylation sites can interfere with the receptor
binding properties, which consequently contributes to virus repli-
cation and fitness [43]. Furthermore, previous studies have shown
that changes in HA glycosylation in AIV can also affect the CMI,
helping AIV to escape T cell recognition [45,46], and inhibit the
approach of clones bearing certain T cell receptors to the
glycopeptide-MHC complex [47]. Dendritic cells mediate the link
between innate and adaptive immune response [48]. A recent
in vitro study showed that influenza virus HA with different
N-glycan patterns could activate dendritic cells [48]. Although a
few studies suggested that N-glycan could play a role in the
regulation of CMI, more experiments are still necessary to fully
understand how it can be modulated.
We found that the Jalisco/37905/2015 has 3 potential addi-
tional N-glycosylation sites on the globular head of HA at the
amino acid position 141 (NGTT), 151 (NPSF), and 182 (NKSA),
which were absent in previous strains, such as Jalisco/12283/2012.
Western blot analysis results demonstrated the higher molecular
weight of the Jalisco/37905/2015 (challenge virus) compared to
the Jalisco/12238/2012 HA. Further, the glycosylation in the posi-
tion 151 and 182 are localized on the globular head of HA in the
antigenic sites A and E, respectively. Mutations in the antigenic
sites have altered recognition of neutralizing antibodies and con-
tributed to escape mutant generation [13,17]. A previous report
highlighted the importance of antigenic site A in HA of H7 AIV
for cross-reactive antibody response [49]. Even though residue
141 is not in the antigenic sites, N-glycosylation in this position
also affects the neutralization by site A antibodies due to its loca-
tion in the protein structure [50]. Next to it, N-glycosylation at
position 142 was shown to be important to the HA and sialic acid
interaction [18], playing a role in virus infectivity and host immune
response observed in different AIV strains [15,18,51]. Thus, these
modifications in the globular head of the H7 HA from Jalisco
2012 to 2015 viruses has potential to play a role in the changes
observed in serological response in the rFPV-H7/2155-vaccinated
birds, which antibodies produced poorly recognize the
Jalisco/37905/2015. Future studies using reverse genetics should
be done to better understand the mechanism of resistance to neu-
tralization conferred specific amino acid modifications and
increases in glycosylation sites in the H7 HA from Mexico strains.
Overall, our data showed that vaccine containing the HA closely
related to recent outbreak H7 strains in Mexico, rFPV-H7/3002,
completely protected chickens from morbidity and mortality fol-
lowing challenge with the 2015 Mexican H7 HPAIV strain,
Jalisco/37905/2015. The vaccine significantly reduced the number
of birds shedding virus and the virus shed titers from the respira-
tory and gastrointestinal tracts. A reduction in virus shedding is an
important outcome of vaccination, which reduces environmental
contamination and subsequent virus transmission from infected
vaccinated flock to uninfected flock [22]. Interesting, prior to June
of 2018, there was no licensed rFPV-H7 AIV in Mexico, although
the rFPV-H5 AIV has been successfully used in the last two decades
[1]. Additionally, rFPV vaccine choice, as opposed to the inactivated
vaccine alone, has advantages as: (a) rapid insertion of any influ-
enza HA gene due to constant antigenic shift and drift among influ-
enza viruses [1,52,53], (b) stimulation of humoral and cellular
2242 M.F. Criado et al. / Vaccine 37 (2019) 2232–2243immunity when given parenterally [1], (c) priming the humoral
immune response to enhance a boost by inactivated vaccines [1],
and (d) mass application and early immunity with hatchery appli-
cation [1,54]. This vaccine was licensed in Mexico on 8 June 2018
and such licensure was based upon these efficacy studies and will
assist in reducing outbreaks of H7N3 HPAI.
H7N3 HPAIV outbreaks in Mexico have been reported to OIE
since 2012 even though biosecurity measures and vaccination
were already established. Molecular analysis showed that Mexican
H7N3 strains have continued to rapidly evolve and recent strains
have multiple amino acid changes and potential additional of N-
glycosylation on the antigenic sites of the HA. It is therefore essen-
tial to continue strict epidemiological surveillance to identify
emerging variant viruses of H7 AIVs circulating in the field. Epi-
demiological surveillance significantly contributes to the develop-
ment of strategies for disease prevention and control, as well as
more suitable vaccine strains for improving vaccination effective-
ness. Altogether, this study confirms the importance of updating
vaccines seeds strains for long-term effective control of H7 HPAIV.Declarations of interest
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